Document Detail


Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
MedLine Citation:
PMID:  2978874     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A study was conducted to determine the effects of glibenclamide on serum lipoproteins, apolipoproteins, thromboxane (TXA2), prostacyclin (PGI2), and beta-thromboglobulin (B-TGL) in patients with newly diagnosed non-insulin-dependent diabetes mellitus (NIDDM). In 20 NIDDM patients, aged 34 to 67 (mean, 53.6) years, without clinical signs of atherosclerotic disease and whose blood sugar level was over 140 mg/dl after four weeks of dietary treatment, fasting blood samples were taken before the beginning of the trial, after four weeks of dietary treatment, and after four and eight weeks of combined dietary and glibenclamide treatment. Pretrial levels of total serum cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) in the diabetic patients did not differ from those in nondiabetic controls, whereas high-density lipoprotein cholesterol (HDL-C) levels and the percentage of TC bound to HDL (HDL-C%) were significantly lower in the patients than in controls. After combined dietary and glibenclamide treatment and the normalization of blood sugar, both HDL-C (mg/dl) levels and HDL-C% levels increased significantly. TC, TG, and LDL-C levels decreased. Levels of apolipoproteins A1 and A2 rose and apolipoprotein B fell, but differences were not significant. TXB2 and 6-keto-PGF1-alpha (the inert metabolites of TXA2 and PGI2) and B-TGL were determined by radioimmunoassay. TXB2 and B-TGL levels decreased significantly after glibenclamide administration, indicating attenuation of platelet aggregation. No changes in PGI2 were observed. The results demonstrate the favorable effect of glibenclamide on lipoproteins and apolipoproteins in NIDDM patients, especially in increasing HDL-C levels and HDL-C%, and in attenuating platelet aggregation as indicated by reduction of TXB2 and B-TGL.
Authors:
J Waysbort; G Regitz; D Chaimowitz; M Tuval; I Nakash; D Brunner
Related Documents :
15754464 - Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 di...
12867534 - Altered distribution of plasma paf-ah between hdls and other lipoproteins in hyperlipid...
10333954 - Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors.
1531244 - Lack of change of lipoprotein (a) concentration with improved glycemic control in subje...
7647824 - Which anthropometric indices of regional adiposity are related to the insulin resistanc...
17639334 - Cytogenetic biomonitoring of the mzamza population exposed to untreated wastewaters.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical therapeutics     Volume:  10     ISSN:  0149-2918     ISO Abbreviation:  Clin Ther     Publication Date:  1988  
Date Detail:
Created Date:  1990-07-26     Completed Date:  1990-07-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7706726     Medline TA:  Clin Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  358-71     Citation Subset:  IM    
Affiliation:
Medical Department A, Edith Wolfson Hospital, Holon, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Apolipoproteins / blood
Apolipoproteins A / blood
Apolipoproteins B / blood
Blood Glucose / metabolism
Cholesterol, HDL / blood
Cholesterol, LDL / blood
Diabetes Mellitus, Type 2 / blood
Epoprostenol / blood*
Female
Glyburide / pharmacology*
Humans
Lipids / blood*
Lipoproteins / blood*
Male
Middle Aged
Thromboxane B2 / blood
Thromboxanes / blood*
beta-Thromboglobulin / metabolism*
Chemical
Reg. No./Substance:
0/Apolipoproteins; 0/Apolipoproteins A; 0/Apolipoproteins B; 0/Blood Glucose; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Lipids; 0/Lipoproteins; 0/Thromboxanes; 0/beta-Thromboglobulin; 10238-21-8/Glyburide; 35121-78-9/Epoprostenol; 54397-85-2/Thromboxane B2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Specific interaction between a subset of the p53 protein family and heat shock proteins hsp72/hsc73 ...
Next Document:  Improved left ventricular function after short-term treatment with fructose-1,6-diphosphate: echocar...